Nanobots and Pharmacological Interventions: A Future Perspective on Eradicating Multidrug Resistant Tuberculosis
International Journal of Sciences and Innovation Engineering · 2025
DOI: 10.70849/ijsci02092025030 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Sciences and Innovation Engineering, 2025. Verfasst von Raj Kumar Mandal. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Multidrug Resistant tuberculosis (MDR-TB) is a major global public health concern due to treatment failure, prolonged treatment duration and non-compliance. These granulomatous lesions cannot be easily surrounded by conventional drug treatment, thus providing an opportunity for survival of M. tuberculosis. All those limitations would be canceled at the revolutionary level, thanks to nanotech and in particular nanobots.
Objective
In this study the application of the nanobots in the future and novel pharmacological agents for improving drug delivery system for TB strains developed resistance and effectiveness of drug therapy in the treatment of MDR-TB will be studied. Materials and methods: Systematic literature review (SLR) for recent updates of drug delivery systems and nanobots design and pharmacological intervention against tuberculosis (anti-TB) using peer-reviewed PubMed, Scopus and Science Direct databases (2015-2025). MDR-TB was chosen as a case study and new technologies were tested theoretically and experimentally for their applicability in treatment applications.
Results
Nanobots have been shown able to navigate complex biological environments while specifically targeting pathology-laden macrophages and the selective delivery of drugs for controlled action. In addition to the recently developed pharmacological agents such as bedaquiline and delamanid, nanoparticle drug delivery would have an effect of sustaining the therapeutic concentration at sites of infection, while avoiding systemic toxicity and potentially shortening the therapeutic time course.
Conclusion
Synergies based on the pharmacological aspects of nanobots are at the developmental stages, but it represents a paradigm shift in the treatment of MDR TB. Further collaborative research could transform these newly developed tools into powerful drugs to stop treatment even from strains of TB that are resistant to those drugs.
Zitieren
APA
Mandal, R. K. (2025). Nanobots and Pharmacological Interventions: A Future Perspective on Eradicating Multidrug Resistant Tuberculosis. International Journal of Sciences and Innovation Engineering. https://doi.org/10.70849/ijsci02092025030
Vancouver
Mandal RK. Nanobots and Pharmacological Interventions: A Future Perspective on Eradicating Multidrug Resistant Tuberculosis. International Journal of Sciences and Innovation Engineering. 2025. doi:10.70849/ijsci02092025030
BibTeX
@article{Mandal2025,
author = {Mandal, Raj Kumar},
title = {Nanobots and Pharmacological Interventions: A Future Perspective on Eradicating Multidrug Resistant Tuberculosis},
journal = {International Journal of Sciences and Innovation Engineering},
year = {2025},
doi = {10.70849/ijsci02092025030}
}
EUVIMED